Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 7/20 | 0.42 |
| ▸ | ADH1C | P00326 | 4/20 | 0.42 |
| ▸ | PHGDH | O43175 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31618698 | 1.00 | ADH1A (0.42) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL12227420 | 0.97 | ADH1A (0.39) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL10453704 | 0.94 | ADH1C (0.35) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL4569251 | 0.85 | — | — | |
| SCHEMBL19143717 | 0.79 | PHGDH (0.40) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL19333233 | 0.79 | ADH1A (0.39) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL12543353 | 0.79 | ADH1A (0.39) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL12543486 | 0.76 | ADH1A (0.36) | ADH1AADH1CPHGDHFAAHMGLL | |
| SCHEMBL19733305 | 0.76 | — | — | |
| SCHEMBL18433477 | 0.75 | ADH1A (0.39) | ADH1AADH1CPHGDHFAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120136646-A | Method for synthesizing benzyl alkyl ketone compound by visible light catalysis | 中国科学院化学研究所 | 2025-06-13 | — | — | CN | claimed |
| CN-120136646-A | Method for synthesizing benzyl alkyl ketone compound by visible light catalysis | 中国科学院化学研究所 | 2025-06-13 | — | — | CN | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20100048594-A1 | USE OF CYTOHESIN INHIBITORS FOR CHEMICALLY INDUCING LONGEVITY | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20100022533-A1 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-28 | — | — | US | disclosed |
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-08 | — | — | US | disclosed |
| US-7592177-B2 | 2-(4-morpholinoanilino)-6-cyclohexylamino-purine; contacting a lineage committed cell (myoblast) with cell dedifferentiates into a multipotent stem cell; for repair of damaged tissues; cardiovascular, neurodegenerative disease and aging; small molecules | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-09-22 | — | — | US | disclosed |
| US-7569604-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-04 | — | — | US | disclosed |
| US-20090105286-A1 | Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITAT (DE) | 2009-04-23 | — | — | US | disclosed |
| US-7326703-B2 | (1,10B-Dihydro-2-(aminocarbonyl-phenyl)-5H-pyrazolo[1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors | TIBOTEC PHARMACEUTICALS LTD (IL) | 2008-02-05 | — | — | US | disclosed |
| US-20070254884-A1 | Compositions and Methods for Inducing Cell Dedifferentiation | THE SCRIPPS RESEARCH INSTITUTE | 2007-11-01 | — | — | US | disclosed |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2007-10-25 | — | — | US | disclosed |
| CN-1541995-A | Novel method for synthesizing gamma-amino acid | 中国科学院成都有机化学研究所 | 2004-11-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | ADH1A 4689/4885ADH1C 4478/4885PHGDH 2418/4885 |
| US-20070254884-A1 | Compositions and Methods for Inducing Cell Dedifferentiation | PAX3, PAX2, ALPG | ADH1A 3157/4885ADH1C 2726/4885PHGDH 1168/4885 |
| US-20100048594-A1 | USE OF CYTOHESIN INHIBITORS FOR CHEMICALLY INDUCING LONGEVITY | IGFBP1, IGFBP2, IGFBP5 | ADH1A 2351/4885ADH1C 1974/4885PHGDH 1135/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | ADH1A 3789/4885ADH1C 3793/4885PHGDH 578/4885 |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | ADH1A 1966/4885ADH1C 3139/4885PHGDH 4327/4885 |
| US-20090105286-A1 | Low-molecular inhibitors of cytohesin-family guanine nucleotide exchange factors | CYTH2, CYTH3, ENTPD5 | ADH1A 4736/4885ADH1C 4782/4885PHGDH 2443/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | ADH1A 2987/4885ADH1C 3071/4885PHGDH 1884/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | ADH1A 2987/4885ADH1C 3071/4885PHGDH 1884/4885 |
| US-20070248624-A1 | (1,10B-Dihydro-2-(Aminocarbonyl-Phenyl)-5h-Pyrazolo[1,5-C][1,3]Benzoxazin-5-Yl)Phenyl Methanone Derivatives as Hiv Viral Replication Inhibitors | POLRMT, MAVS, DHX15 | ADH1A 919/4885ADH1C 401/4885PHGDH 1479/4885 |
| US-20100022533-A1 | COMPOSITIONS AND METHODS FOR INDUCING CELL DEDIFFERENTIATION | ALPG, PAX3, RARG | ADH1A 1807/4885ADH1C 1574/4885PHGDH 605/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | ADH1A 4617/4885ADH1C 4526/4885PHGDH 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.